Paradice Investment Management Decreased Its Sothebys (BID) Stake; Opko Health (OPK) Sentiment Is 0.84

May 21, 2018 - By Kurt Siggers

Sotheby's (NYSE:BID) Logo

Paradice Investment Management Llc decreased Sothebys (BID) stake by 2.75% reported in 2017Q4 SEC filing. Paradice Investment Management Llc sold 30,121 shares as Sothebys (BID)’s stock declined 1.98%. The Paradice Investment Management Llc holds 1.06 million shares with $54.93M value, down from 1.09M last quarter. Sothebys now has $2.94B valuation. The stock decreased 0.68% or $0.39 during the last trading session, reaching $56.66. About 91,405 shares traded. Sotheby's (NYSE:BID) has risen 12.14% since May 21, 2017 and is uptrending. It has outperformed by 0.59% the S&P500.

Opko Health Inc (OPK) investors sentiment decreased to 0.84 in 2017 Q4. It’s down -0.30, from 1.14 in 2017Q3. The ratio turned negative, as 77 investment managers opened new or increased equity positions, while 92 trimmed and sold stakes in Opko Health Inc. The investment managers in our database now own: 119.15 million shares, down from 119.76 million shares in 2017Q3. Also, the number of investment managers holding Opko Health Inc in top ten equity positions decreased from 3 to 1 for a decrease of 2. Sold All: 32 Reduced: 60 Increased: 53 New Position: 24.

Paradice Investment Management Llc increased Itt Inc stake by 35,426 shares to 1.61M valued at $85.95M in 2017Q4. It also upped Astronics Corp (NASDAQ:ATRO) stake by 76,870 shares and now owns 573,365 shares. Orthofix Intl N V (NASDAQ:OFIX) was raised too.

Since March 5, 2018, it had 0 insider buys, and 2 insider sales for $3.45 million activity. DELANEY KEVIN M also sold $94,164 worth of Sotheby's (NYSE:BID) shares. The insider Reza Olivier sold 65,000 shares worth $3.36 million.

More notable recent Sotheby's (NYSE:BID) news were published by: Globenewswire.com which released: “Sotheby’s Reports 2018 First Quarter Financial Results” on May 03, 2018, also Livetradingnews.com with their article: “Sotheby’s (NYSE:BID) Fine Wine Sale Indicate Prices are Rebounding” published on April 22, 2018, Seekingalpha.com published: “Sotheby’s up 3% post Q1 results” on May 04, 2018. More interesting news about Sotheby's (NYSE:BID) were released by: Seekingalpha.com and their article: “Sotheby’s (BID) CEO Thomas Smith on Q1 2018 Results – Earnings Call Transcript” published on May 06, 2018 as well as Prnewswire.com‘s news article titled: “A Billion Dollar Week of Sales at Sotheby’s Worldwide” with publication date: May 18, 2018.

Investors sentiment increased to 0.86 in 2017 Q4. Its up 0.14, from 0.72 in 2017Q3. It increased, as 27 investors sold BID shares while 69 reduced holdings. 24 funds opened positions while 59 raised stakes. 46.14 million shares or 2.89% less from 47.51 million shares in 2017Q3 were reported. Wright Invsts Service Incorporated holds 0.08% of its portfolio in Sotheby's (NYSE:BID) for 4,497 shares. Hsbc Public Ltd Com reported 4,809 shares. Geode Capital Ltd Com accumulated 327,106 shares. Adams Diversified Equity Fund Incorporated owns 16,000 shares. D E Shaw owns 529,276 shares or 0.04% of their US portfolio. Art Advsr Ltd Liability Corporation invested 0.1% of its portfolio in Sotheby's (NYSE:BID). National Bank Of Montreal Can stated it has 0% of its portfolio in Sotheby's (NYSE:BID). State Street has invested 0.01% in Sotheby's (NYSE:BID). Manufacturers Life Co The has 89,845 shares for 0% of their portfolio. Hall Laurie J Trustee has invested 0.01% of its portfolio in Sotheby's (NYSE:BID). Moreover, Yorktown Mgmt And Research Communication has 0.08% invested in Sotheby's (NYSE:BID) for 5,050 shares. Cornerstone Advsrs Inc has invested 0% in Sotheby's (NYSE:BID). Los Angeles Cap Mngmt Equity Research has invested 0% in Sotheby's (NYSE:BID). Citadel Advsr Limited Liability Corporation holds 0% of its portfolio in Sotheby's (NYSE:BID) for 36,762 shares. Pacad Inv holds 0.02% or 2,000 shares.

Among 10 analysts covering Sotheby’s (NYSE:BID), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Sotheby’s had 19 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was initiated by Standpoint Research on Wednesday, January 20 with “Buy”. As per Thursday, April 14, the company rating was downgraded by Standpoint Research. The firm earned “Buy” rating on Thursday, September 28 by Cowen & Co. TheStreet downgraded the stock to “Hold” rating in Tuesday, July 28 report. The firm has “Hold” rating by Stifel Nicolaus given on Thursday, February 11. The company was maintained on Friday, February 2 by Cowen & Co. The firm has “Buy” rating by Cowen & Co given on Thursday, March 1. Sitfel downgraded Sotheby's (NYSE:BID) on Thursday, February 11 to “Hold” rating. Cowen & Co maintained the shares of BID in report on Friday, November 3 with “Buy” rating. As per Thursday, September 3, the company rating was maintained by Williams Capital Group.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The company has market cap of $2.16 billion. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. It currently has negative earnings. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.

Analysts await OPKO Health, Inc. (NASDAQ:OPK) to report earnings on August, 14. They expect $-0.07 earnings per share, down 75.00% or $0.03 from last year’s $-0.04 per share. After $-0.08 actual earnings per share reported by OPKO Health, Inc. for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

More notable recent OPKO Health, Inc. (NASDAQ:OPK) news were published by: Nasdaq.com which released: “Here’s Why OPKO Health Dropped as Much as 23% Today” on May 18, 2018, also Fool.com with their article: “Better Buy: Opko Health, Inc. (OPK) vs. Myriad Genetics (MYGN)” published on May 18, 2018, Nasdaq.com published: “OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test” on May 18, 2018. More interesting news about OPKO Health, Inc. (NASDAQ:OPK) were released by: Globenewswire.com and their article: “OPKO Health Reports First Quarter 2018 Financial Results” published on May 08, 2018 as well as Globenewswire.com‘s news article titled: “OPKO Health Appoints Geoff Monk General Manager at BioReference Laboratories” with publication date: May 01, 2018.

The stock decreased 3.26% or $0.1299 during the last trading session, reaching $3.8601. About 2.81M shares traded. OPKO Health, Inc. (OPK) has declined 60.81% since May 21, 2017 and is downtrending. It has underperformed by 72.36% the S&P500.

Rk Asset Management Llc holds 3.86% of its portfolio in OPKO Health, Inc. for 932,752 shares. Oracle Investment Management Inc owns 3.83 million shares or 3.73% of their US portfolio. Moreover, Jaffetilchin Investment Partners Llc has 1.54% invested in the company for 943,039 shares. The Israel-based Mivtachim The Workers Social Insurance Fund Ltd. (Under Special Management) has invested 0.78% in the stock. Lehman Financial Resources Inc., a Pennsylvania-based fund reported 257,703 shares.

Sotheby's (NYSE:BID) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Kurt Siggers

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: